Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20394131 | 0.85 | FEN1 (0.38) | FEN1 | |
| SCHEMBL20406180 | 0.84 | GPBAR1 (0.42) | FEN1 | |
| SCHEMBL18661523 | 0.83 | AHR (0.40) | FEN1 | |
| SCHEMBL20394475 | 0.83 | FEN1 (0.35) | FEN1 | |
| SCHEMBL20394265 | 0.81 | NPBWR1 (0.42) | — | |
| SCHEMBL20394211 | 0.79 | PDE4A (0.41) | — | |
| SCHEMBL18661528 | 0.78 | TOP1 (0.41) | — | |
| SCHEMBL18661463 | 0.78 | KDR (0.42) | — | |
| SCHEMBL20394494 | 0.77 | PDE10A (0.38) | FEN1 | |
| SCHEMBL20394208 | 0.76 | PDE10A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647675-B2 | Biaryl derivative and medicine containing same | MAN2B1, CBR3, MANBA | FEN1 4478/4885 |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | MAN2B1, CBR3, MANBA | FEN1 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.